Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab

Elotuzumab is a humanized monoclonal antibody targeting the extracellular domain of signaling lymphocytic activation molecule F7 (SLAMF7) highly expressed in multiple myeloma cells. Upon binding to myeloma cells, elotuzumab exerts its cytotoxic effects through antibody-dependent cellular cytotoxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Einsele, Hermann, Schreder, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026292/
https://www.ncbi.nlm.nih.gov/pubmed/27695618
http://dx.doi.org/10.1177/2040620716657993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026292/
https://www.ncbi.nlm.nih.gov/pubmed/27695618
http://dx.doi.org/10.1177/2040620716657993

Ejemplares similares